Junior debt in a crowdfunding deal just got its cure period tested when the senior filed a notice of default

The assumption doing the most work in any crowdfunded junior position is that the platform's aggregation structure gives the tranche coherent decision-making capacity. This deal illustrates exactly where that assumption breaks down.

Two mechanics are worth separating. First, the cure right itself. In most mezz structures, the cure right runs to the mezz lender as an entity, meaning the platform's SPV, not to individual investors who hold interests in that SPV. So the 90-day clock is technically the platform's clock to beat, not a collective action problem among retail holders. The actual problem is capital assembly. The platform has to either call capital from its LP investors, draw on a reserve it probably does not hold at that scale, or find a single holder willing to fund the cure and sort out reimbursement later. That last path is what saved the position here, and it required the institutional co-investor to have both the contractual standing and the commercial incentive to act unilaterally.

Second, and this is where the operating agreement language matters enormously: whether any single holder can cure on behalf of the tranche without unanimous or majority consent, and whether doing so creates a preferred recovery right against the other tranche participants. A tax or securities attorney needs to read that document before you commit capital to a junior position, not after a notice of default lands.

The risk you did not name is what happens when the institutional anchor is absent and the platform itself has no reserve mechanism. The cure right expires, the mezz is wiped in the senior foreclosure, and the retail holders have recourse only against the sponsor, who is already in default.

When you reviewed this deal's offering documents, did the platform's SPV agreement specify a cure funding mechanism, or was the process simply silent on how the entity would assemble that capital if the sponsor stopped paying?

The 60 percent retail holders being passengers is exactly what I expected to read, and I've been saying this out loud for two years to people who look at me like I'm being dramatic. I put LP money into a mixed-use deal in Shreveport where the capital stack had a similar layering situation, and before I wired anything I spent two calls with the GP asking specifically who else was in the position and what their liquidity profile looked like in a stress scenario. Got vague answers both times, which told me something. What decided my comfort level was the GP's personal balance sheet commitment, not the other LPs, because I had no visibility into them at all. The 41k cure number is almost beside the point, it's a small number relative to the 680k mezz position, but the mechanism for assembling it inside a 90-day window through a platform built for retail ticket sizes was clearly never stress-tested when the deal was underwritten. What I'd want to know from the poster is whether the platform disclosed the investor mix in the offering documents at all, or whether that information only became visible once the default happened.

The judicial versus non-judicial split is the part of this I wish more people would sit with before they wire anything. I looked at a deal in Georgia last year, non-judicial state, and the cure window in the intercreditor was 30 days from the senior's notice. The platform's own subscription process for new capital takes 7 to 10 business days on a good week. You are already a third of the way through your window before anyone has even decided to act. In Massachusetts, at least the judicial timeline gives you more runway, but I have been in deals where the intercreditor was negotiated in a state with one set of rules and the property sat in another, and the governing law clause was doing a lot of work that nobody in the deal summary bothered to explain.

What I have not seen answered cleanly in any offering memo I have read is whether the platform itself holds any capital reserve or credit facility specifically for cure scenarios, because if the answer is no and there is no institutional anchor in the tranche, the retail holders are structurally dependent on a good outcome at the sponsor level and nothing else. The operating agreement question you raised about standing to cure is real, but there is a layer before that: does the platform even have the operational capacity to call capital from investors and deploy it inside a 30 or 90 day window, and has that process ever actually been tested? What platform was this on, because I want to know whether they published anything about how the cure decision got made and who authorized the institutional holder to act.

The 28-month hold framing is what I keep coming back to. Secondary market exits do not compress on command, and a 48-unit garden-style is not the asset that attracts a deep buyer pool under any rate environment, let alone the one sponsors were staring at in months 18 through 24 of most recent vintage deals. The sponsor probably knew by month 14 or 15 that the exit window was slipping. The question I would want answered is whether any of that showed up in investor updates before month 19, because if the quarterly letters were still projecting an on-time exit at month 16 or 17, that is a separate problem from the cure mechanics.

On the disclosure piece, what you are pointing at matters a lot and I do not think most retail participants on these platforms read far enough into the operating agreement to find it. The difference between "an investor holding X percent may cure unilaterally" and "cure requires majority consent of the tranche" is the difference between having a real protective mechanism and having language that sounds protective. I came into my Texas LP position assuming the structural protections I read about in the deck were reflected in the actual LLC agreement, and the K-1 situation that followed taught me that the deck and the agreement are not always the same document in spirit. Did the platform in this case publish the actual mezz intercreditor agreement to all investors at subscription, or just a summary of it?